# MIMRYLO™ (rusfertide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/rusfertide

> The FDA approved MIMRYLO™ (rusfertide), sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on November 5, 2026 for erythrocytosis in adults with polycythemia vera.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | MIMRYLO™ (rusfertide) |
| Codes | TAK-121, PTG-300 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | erythrocytosis in adults with polycythemia vera, [polycythemia vera"](https://sec-api.dev/indications/polycythemia-vera), with pv, [polycythemia vera](https://sec-api.dev/indications/polycythemia-vera), To treat erythrocytosis in adults with polycythemia vera |
| Modality | peptide |
| FDA designations | breakthrough, fast track, orphan, priority review |

## Timeline

### March 3, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: Polycythemia Vera".
- First seen 2025-02-21, last confirmed 2025-12-08.
- SEC Form 8-K (accession 0001395064-25-000164): "The topline results of this study were announced on March 3, 2025, in "Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera"." https://www.sec.gov/Archives/edgar/data/1395064/000139506425000164/form6k_120825.htm
- SEC Form 8-K (accession 0001395064-25-000071): "The topline results of this study were disclosed on March 3, 2025, in "Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera"." https://www.sec.gov/Archives/edgar/data/1395064/000139506425000071/form6k-1_060225.htm
- SEC Form 8-K (accession 0001395064-25-000034): "OSAKA, Japan, March 3, 2025 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") and Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced positive topline results for the Phase 3 VERIFY study of rusfertide in patients with polycythemia vera (PV)." https://www.sec.gov/Archives/edgar/data/1395064/000139506425000034/form6k-2_030325.htm
- SEC Form 8-K (accession 0001395064-25-000034): "NEWARK, California, OSAKA, Japan and CAMBRIDGE, Massachusetts, March 3, 2025 - Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment." https://www.sec.gov/Archives/edgar/data/1395064/000139506425000034/form6k-2_030325.htm
- Press release filed with the SEC (EX-99) (accession 0001395064-25-000063): "Development code: TAK-121 / Generic name: rusfertide - In March 2025, Takeda and Protagonist Therapeutics announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment." https://www.sec.gov/Archives/edgar/data/1395064/000139506425000063/a2025_convocation.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-019516): "Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment." https://www.sec.gov/Archives/edgar/data/1377121/000110465925019516/tm258056d1_ex99-1.htm
- SEC Form 10-K (accession 0001558370-25-001317): "We expect to announce top-line data for the trial's 32-week primary efficacy endpoint in March 2025, potentially leading to an NDA filing in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1377121/000155837025001317/ptgx-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001317): "We expect to announce top-line data for the trial's 32-week primary efficacy endpoint in the first quarter of 2025, potentially leading to an NDA filing in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1377121/000155837025001317/ptgx-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-015897): "Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in March 2025" https://www.sec.gov/Archives/edgar/data/1377121/000110465925015897/tm257151d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-015897): ""Protagonist is quickly approaching multiple late-stage transformational events expected in the first quarter of this year, including the topline results from the VERIFY Phase 3 study of rusfertide in polycythemia vera and from the ANTHEM Phase 2b ulcerative colitis study of icotrokinra", said Dinesh V. Patel, Ph.D., the Company's President and CEO." https://www.sec.gov/Archives/edgar/data/1377121/000110465925015897/tm257151d1_ex99-1.htm
- SEC Form 10-Q (accession 0001558370-25-006530): "In March 2025, we announced positive top-line data for the trial's 32-week primary efficacy endpoint, potentially leading to an NDA filing in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1377121/000155837025006530/ptgx-20250331x10q.htm
- SEC Form 10-Q (accession 0001104659-25-107816): "In March 2025, we announced positive top-line data for the trial's 32-week primary efficacy endpoint, potentially leading to an NDA filing by the end of 2025." https://www.sec.gov/Archives/edgar/data/1377121/000110465925107816/ptgx-20250930x10q.htm

### Mar 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: with PV.
- First seen 2026-05-26, last confirmed 2026-05-26.
- Press release filed with the SEC (EX-99) (accession 0001395064-26-000162): "- 45 - - In March 2026, Takeda and Protagonist Therapeutics announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide for the treatment of adults with PV." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm

### May 5, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-05-05, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-055629): "March 2, Takeda and Protagonist announced that the U.S. FDA accepted the New Drug Application for rusfertide and granted" https://www.sec.gov/Archives/edgar/data/1377121/000110465926055629/tm2613550d1_ex99-1.htm

### Q3 2026: PDUFA date

- Status: completed, approved. Date confidence: quarter.
- First seen 2026-03-02, last confirmed 2026-05-26.
- Press release filed with the SEC (EX-99) (accession 0001395064-26-000162): "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm
- SEC Form 8-K (accession 0001395064-26-000007): "−Prescription Drug User Fee Act (PDUFA) Target Action Date is in the Third Quarter of this Calendar Year" https://www.sec.gov/Archives/edgar/data/1395064/000139506426000007/form6k_030226.htm
- SEC Form 8-K (accession 0001395064-26-000007): "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000007/form6k_030226.htm
- FDA novel drug approvals: "Mimrylo | rusfertide | 8/28/2026 | To treat erythrocytosis in adults with polycythemia vera" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

### Aug 2026: PDUFA date

- Status: completed, approved. Date confidence: month.
- First seen 2026-05-05, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-091099): "As announced on March 2nd, the NDA for rusfertide was accepted by the FDA and granted Priority Review in Q1 2026, with a PDUFA goal date in August 2026." https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-091123): "The NDA for rusfertide is currently under priority review by the FDA, with a Prescription Drug User Fee Act target action date in August 2026." https://www.sec.gov/Archives/edgar/data/1377121/000110465926091123/ptgx-20260630x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-091099): "NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026" https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-055629): "The FDA set a PDUFA goal date in August 2026." https://www.sec.gov/Archives/edgar/data/1377121/000110465926055629/tm2613550d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-055661): "The NDA for rusfertide is currently under priority review by the FDA, with a Prescription Drug User Fee Act target action date in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1377121/000110465926055661/ptgx-20260331x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-055629): "Review by FDA, with a Prescription Drug User Fee Act target action date in the third quarter of 2026" https://www.sec.gov/Archives/edgar/data/1377121/000110465926055629/tm2613550d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-091123): "The NDA was granted priority review by the FDA, with a Prescription Drug User Fee Act target action date in August 2026." https://www.sec.gov/Archives/edgar/data/1377121/000110465926091123/ptgx-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-055661): "The NDA was granted priority review by the FDA, with a Prescription Drug User Fee Act target action date in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1377121/000110465926055661/ptgx-20260331x10q.htm
- FDA novel drug approvals: "Mimrylo | rusfertide | 8/28/2026 | To treat erythrocytosis in adults with polycythemia vera" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

### August 5, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-08-05, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-091099): "As announced on March 2nd, the NDA for rusfertide was accepted by the FDA and granted Priority Review in Q1 2026, with a PDUFA goal date in August 2026." https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm

### August 28, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat erythrocytosis in adults with polycythemia vera.
- First seen 2026-08-31, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Mimrylo | rusfertide | 8/28/2026 | To treat erythrocytosis in adults with polycythemia vera" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
- openFDA Drugs@FDA: "NDA220605 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20260828, review_priority PRIORITY; sponsor_name TAKEDA PHARMS AM; product MIMRYLO (RUSFERTIDE ACETATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220605%22
- SEC Form 8-K (accession 0001395064-26-000331): "OSAKA, Japan and CAMBRIDGE, Massachusetts, August 28, 2026 - Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLOTM (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000331/form6k_082826.htm
- SEC Form 8-K (accession 0001395064-26-000345): "-In August 2026, Takeda announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for MIMRYLO for the treatment of erythrocytosis in adults with polycythemia vera (PV)." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000345/form6k-2_102926.htm

### late 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-05-05, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-055629): "PN-881 (oral IL-17 antagonist peptide): The Company expects completion of Phase 1 study by mid-2026 and initiation of a Phase 2 study by end of 2026." https://www.sec.gov/Archives/edgar/data/1377121/000110465926055629/tm2613550d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-091099): "PN-477 (triple GLP1/GIP/GCG agonist peptide for obesity): Phase 1 study with the injectable (sc) PN-477 has begun, and initiation of a Phase 1 study with the oral (o) formulation of PN-477 is anticipated in first half of 2027." https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm

### November 5, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: erythrocytosis in adults with polycythemia vera.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-123351): "Protagonist announced that its partner Takeda received U.S. Food and Drug Administration (FDA) approval of MIMRYLO for the treatment of erythrocytosis in adults with polycythemia vera (PV)." https://www.sec.gov/Archives/edgar/data/1377121/000110465926123351/tm2629043d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-123351): "These payments, which were received in cash in October 2026, consisted of a further $200.0 million opt-out fee and a separate $75.0 million milestone triggered by the FDA approval of MIMRYLO." https://www.sec.gov/Archives/edgar/data/1377121/000110465926123351/tm2629043d1_ex99-1.htm

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Polycythemia Vera.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07648030 (A Study of Rusfertide in Japanese Adults With Polycythemia Vera): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07648030

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Polycythemia Vera.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07648030 (A Study of Rusfertide in Japanese Adults With Polycythemia Vera): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07648030

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Polycythemia Vera.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07765602 (A Study of Rusfertide in Adults With Polycythemia Vera in China): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07765602

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Polycythemia Vera.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07765602 (A Study of Rusfertide in Adults With Polycythemia Vera in China): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07765602

## Same indication

- [PRT12396](https://sec-api.dev/pdufa/prt12396) (PRLD)

Calendar months: [October 2027](https://sec-api.dev/fda-calendar/2027-10), [July 2028](https://sec-api.dev/fda-calendar/2028-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/rusfertide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MIMRYLO™ (rusfertide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/rusfertide

```bibtex
@misc{secapidev_pdufa_rusfertide_20261116,
  title        = {MIMRYLO™ (rusfertide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/rusfertide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_rusfertide_20261116","title":"MIMRYLO™ (rusfertide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/rusfertide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
